	US 12,329,791 B2
	Mixture of probiotic bacteria strains for use in the treatment of allergic asthma and with recurrent wheezing, preferably in paediatric subjects
Vera Mogna, Novara (IT); Marco Pane, Novara (IT); and Angela Amoruso, Novara (IT)
Assigned to PROBIOTICAL S.P.A., Novara (IT)
Appl. No. 17/436,847
Filed by PROBIOTICAL S.P.A., Novara (IT)
PCT Filed Mar. 6, 2020, PCT No. PCT/IB2020/051961 § 371(c)(1), (2) Date Sep. 7, 2021, PCT Pub. No. WO2020/178794, PCT Pub. Date Sep. 10, 2020.
Claims priority of application No. 102019000003351 (IT), filed on Mar. 7, 2019.
Prior Publication US 2022/0175855 A1, Jun. 9, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/745 (2015.01); A61K 35/74 (2015.01); A61P 11/00 (2006.01); A61P 11/06 (2006.01); A61K 35/747 (2015.01)

CPC A61K 35/745 (2013.01) [A61K 35/74 (2013.01); A61P 11/00 (2018.01); A61P 11/06 (2018.01); A61K 35/747 (2013.01)]

10 Claims

1. A method for treating a disorder or ailment or disease of the respiratory airways of a subject in need thereof, comprising

administering to the subject an effective amount of an isolated strain Bifidobacterium breve (B632) deposited under accession number DSM 24706.